288 related articles for article (PubMed ID: 25517966)
1. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
Osman M; Pagnoux C; Dryden DM; Storie D; Yacyshyn E
PLoS One; 2014; 9(12):e115026. PubMed ID: 25517966
[TBL] [Abstract][Full Text] [Related]
2. Biologic treatment of large-vessel vasculitides.
Schäfer VS; Zwerina J
Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
[TBL] [Abstract][Full Text] [Related]
3. Biotherapies in large vessel vasculitis.
Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
[TBL] [Abstract][Full Text] [Related]
4. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
5. A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis.
Misra DP; Sharma A; Kadhiravan T; Negi VS
Autoimmun Rev; 2017 Feb; 16(2):179-191. PubMed ID: 27988436
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis.
Koster MJ; Matteson EL; Warrington KJ
Curr Opin Rheumatol; 2016 May; 28(3):211-7. PubMed ID: 26885650
[TBL] [Abstract][Full Text] [Related]
7. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
[TBL] [Abstract][Full Text] [Related]
8. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
[TBL] [Abstract][Full Text] [Related]
10. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Hellmich B; Agueda A; Monti S; Buttgereit F; de Boysson H; Brouwer E; Cassie R; Cid MC; Dasgupta B; Dejaco C; Hatemi G; Hollinger N; Mahr A; Mollan SP; Mukhtyar C; Ponte C; Salvarani C; Sivakumar R; Tian X; Tomasson G; Turesson C; Schmidt W; Villiger PM; Watts R; Young C; Luqmani RA
Ann Rheum Dis; 2020 Jan; 79(1):19-30. PubMed ID: 31270110
[TBL] [Abstract][Full Text] [Related]
11. MRI parametric monitoring of biological therapies in primary large vessel vasculitides: a pilot study.
Spira D; Xenitidis T; Henes J; Horger M
Br J Radiol; 2016; 89(1058):20150892. PubMed ID: 26649990
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.
Rathore U; Thakare DR; Patro P; Agarwal V; Sharma A; Misra DP
Clin Rheumatol; 2022 Jan; 41(1):33-44. PubMed ID: 34729652
[TBL] [Abstract][Full Text] [Related]
13. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic update in large vessel vasculitides.
Pérez-Esteban S; González-Gay MA; Castañeda S
Rev Clin Esp (Barc); 2013 Oct; 213(7):338-46. PubMed ID: 23683962
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.
Evans J; Steel L; Borg F; Dasgupta B
RMD Open; 2016; 2(1):e000137. PubMed ID: 26819753
[TBL] [Abstract][Full Text] [Related]
17. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for giant cell arteritis.
Antonio AA; Santos RN; Abariga SA
Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
Shuai ZQ; Zhang CX; Shuai ZW; Ge SL
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
[TBL] [Abstract][Full Text] [Related]
20. Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors.
Matsumoto K; Suzuki K; Takeshita M; Takeuchi T; Kaneko Y
Front Immunol; 2023; 14():1197342. PubMed ID: 37197652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
